CORE-015: GENOMICS SHARED RESOURCE (GSR) PROJECT SUMMARY / ABSTRACT Genomics services, with its wide range of varying technologies and complexities, are essential for cancer research. A centralized resource is needed to conduct these analyses due to the expense of the instruments and the requisite expertise. The OSUCCC Genomics Shared Resource (GSR) is a state-of-the-art laboratory that has the following Specific Aims: 1) to sequence DNA and RNA templates, using next generation sequencing platforms (i.e. Illumina MiSeq and HiSeq 2500, and Ion Torrent PGM instruments) and capillary Sanger sequencing and genotyping (using ABI 3730 DNA Analyzers); 2) to use sensitive molecular hybridization methods to detect and quantify RNA transcript expression levels and structures such as splicing and/or DNA copy numbers and variation, including digital (Nanostring) and state-of-the-art microarray (Affymetrix) platforms; and, 3) to perform polymerase chain reaction (PCR)-based amplification to detect, quantify and confirm copy number variants, single nucleotide variants and small insertion/deletion polymorphisms including quantitative PCR (ABI 3730 DNA Analyzer) and by high throughput digital and custom PCR assay (QuantStudio 12K Flex and OpenArray) methods. The GSR was integrated as a single entity in 2012, bringing the prior OSUCCC MicroArray Shared Resource and Nucleic Acid Shared Resource together to enhance efficiency and facilitate user ease and choice of assays. The Director is Dr. David Symer (MBCG) and the Senior Faculty Advisor is Dr. Carlo Croce (MBCG). The GSR is located in the Biomedical Research Tower (BRT) and so is centrally located to most of the OSUCCC laboratories. Over the last grant period, the OSUCCC purchased new equipment and/or upgrades to stay on the cutting edge of genomics research, totaling $3,110,511. As a measure of the highly significant value of services provided by the GSR to OSUCCC researchers over the last grant period, the GSR provided genomics services to 175 OSUCCC members. A total of 375 publications incorporated GSR services of which 51 had a journal impact factor greater than 10. The GSR has supported 104 NCI grants, including 16 programmatic grants (i.e., N01, P50, P01, U10, U54), 57 R01s and 20 R21s. Over the next five year period, the GSR will continue to update its technological platforms and expertise in genomics methods and will continue to innovate with new assays and approaches in this very fast-paced area of research. Future plans include implementation of new methods in long-read sequencing and acquisition of robotic systems to generate reproducible high quality libraries for deep sequencing prepared from technically challenging and more limited starting materials. The GSR leverages extensive institutional support and seeks only 22.1% support from CCSG funds. The GSR is part of the Diagnostics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843874
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications